777 reports of this reaction
3.2% of all PALIVIZUMAB reports
#7 most reported adverse reaction
DYSPNOEA is the #7 most commonly reported adverse reaction for PALIVIZUMAB, manufactured by Swedish Orphan Biovitrum AB (publ). There are 777 FDA adverse event reports linking PALIVIZUMAB to DYSPNOEA. This represents approximately 3.2% of all 24,586 adverse event reports for this drug.
Patients taking PALIVIZUMAB who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among PALIVIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for PALIVIZUMAB:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 777 FDA reports for PALIVIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.2% of all adverse event reports for PALIVIZUMAB, making it a notable side effect.
If you experience dyspnoea while taking PALIVIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.